2 terminated. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Terminated 2 |
| Phase 2 | 1 | Terminated 1 |
Follow Pmm2-CDG: new trials by email Literature Review of Pmm2-CDG trials Research Report on Pmm2-CDG
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral Epalrestat Therapy in Pediatric Subjects With PMM2-CDG Epalrestat, Placebo - Pmm2-CDG, Phosphomannomutase 2 Deficiency | Phase 3 | Terminated | Maggie's Pearl, LLC | 42 | 2022-11-10 | 2025-09-25 |
| Acetazolamide Efficacy in Ataxia in PMM2-CDG Placebo, Acetazolamide - Pmm2-CDG, CDG1A | Phase 2 / Phase 3 | Terminated | Mayo Clinic | 25 | 2021-03-17 | 2025-03-20 |
Congenital disorder of glycosylation type 1A (2)
Acetazolamide (1) · Gelatin (1) · Lactose (1) · epalrestat (1)
Maggie's Pearl, LLC (1) · Mayo Clinic (1)
United States (2)